Back to top
more

Genmab (GMAB)

(Delayed Data from NSDQ)

$21.98 USD

21.98
957,744

+0.20 (0.92%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $21.98 0.00 (0.00%) 5:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

John Blank headshot

An August Trading Lull? Global Week Ahead

by John Blank

After the nonfarm payroll print, this week looks fairly quiet on the macro data front. It is the summer holiday period of August in the Western Hemisphere.

Zacks Equity Research

Sarepta to Report Q2 Earnings: What's in Store for the Stock?

by Zacks Equity Research

SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.

Zacks Equity Research

Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?

by Zacks Equity Research

TECH eyes modest Q4 growth as strong reagent and instrumentation demand offsets NIH and tariff concerns.

Zacks Equity Research

GMAB vs. ACAD: Which Stock Is the Better Value Option?

by Zacks Equity Research

GMAB vs. ACAD: Which Stock Is the Better Value Option?

Zacks Equity Research

Will Escalating Medical Costs Dampen Centene's Q2 Earnings?

by Zacks Equity Research

CNC's Q2 earnings are likely to have felt the pinch as rising medical costs pressure margins despite higher premium revenues.

Zacks Equity Research

Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View

by Zacks Equity Research

THC's Q2 earnings benefit on the back of strong volumes, facility buyouts, higher acuity and favorable payer mix. It currently expects 2025 adjusted EPS within $15.55-$16.21, up from the earlier view of $11.99-$13.12.

Zacks Equity Research

Genmab (GMAB) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Genmab (GMAB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Genmab (GMAB) points to a 40% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

GMAB or RGEN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GMAB vs. RGEN: Which Stock Is the Better Value Option?

Zacks Equity Research

Should Value Investors Buy Genmab (GMAB) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

GMAB vs. QGEN: Which Stock Is the Better Value Option?

by Zacks Equity Research

GMAB vs. QGEN: Which Stock Is the Better Value Option?

Zacks Equity Research

Genmab (GMAB) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Genmab (GMAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Are Investors Undervaluing Genmab (GMAB) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Kinjel Shah headshot

AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?

by Kinjel Shah

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.

Zacks Equity Research

Is the Options Market Predicting a Spike in Genmab (GMAB) Stock?

by Zacks Equity Research

Investors need to pay close attention to Genmab (GMAB) stock based on the movements in the options market lately.

Zacks Equity Research

Is Genmab (GMAB) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

GMAB or INCY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GMAB vs. INCY: Which Stock Is the Better Value Option?

Zacks Equity Research

Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround

by Zacks Equity Research

Genmab (GMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Kinjel Shah headshot

Should You Buy AbbVie Stock After Recent Parkinson's Study Success?

by Kinjel Shah

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.

Kinjel Shah headshot

AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?

by Kinjel Shah

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.

Zacks Equity Research

AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use

by Zacks Equity Research

AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.

Zacks Equity Research

Wall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 45.1% upside potential for Genmab (GMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Nalak Das headshot

Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat

by Nalak Das

Two biotech bigwigs set to beat on earnings next week are: ILMN, GMAB.

Kinjel Shah headshot

Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?

by Kinjel Shah

Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.

Zacks Equity Research

All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy

by Zacks Equity Research

Genmab (GMAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).